• Dr. Mahendra S Rao, MD, PhD
    Dr. Mahendra is a researcher known for his work involving human embryonic stem cells and other somatic stem cells. Rao received his MD from Bombay University, India, and then earned a PhD in developmental neurobiology from California Institute of Technology.
    After postdoctoral work at Case Western Reserve, he became an independent researcher at University of Utah. Next he joined the National Institute of Aging, where he studied neural progenitor cells and their potential clinical use. Dr. Rao was also the VP of Regenerative Medicine at Life Technologies. Additionally, he co-founded Q Therapeutics, a stem-cell research firm and serves on USDA Cellular Tissue and Gene Therapies advisory committee and more. Rao also holds a joint research appointment in NIAMS and NINDS. In 2011, Rao was appointed Director of the National Institute of Health Center for Regenerative Medicine. He published more than 200 scientific articles in leading journals.

    Prof. Ofer Binah
    Prof. Ofer Binah is the Head of the Department of Physiology and Biophysics at the Rappaport Faculty of Medicine since 1982. Ofer Binah is a cardiac physiologists working for the past 33 years on research topics related to cellular electrophysiology, mechanics and signaling pathways focusing on the IP3 cascade. In addition, Ofer Binah investigated the cellular mechanisms whereby cytotoxic T lymphocytes destroy cardiomyocytes in the course of heart transplant rejection and inflammatory heart diseases. Since 2001 Binah (a co-author on the Kehat et al 2001 paper in JCI) is investigating the functional properties of human embryonic stem cells-derived cardiomyocytes, and have published several papers in this area. Several years ago Binah has begun investigating iPSC-derived cardiomyocytes generated from both dermal fibroblasts and keratinocytes, from healthy volunteers and from patients with inherited cardiac pathologies. Thus, the extensive experience and expertise and of Prof. Ofer Binah constitute a solid basis for participating in Accellta's Scientific Advisory Board.
     
    Dr. Yaqub Hanna
    Dr. Hanna earned a BSc in Medical Sciences, an MSc in Microbiology and Immunology, and a PhD/MD in clinical medicine, all at the Hebrew University of Jerusalem, where he was among the top five percent of all Israeli medical school graduates. He conducted postdoctoral research at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. He joined the Weizmann Institute in 2011.
    Dr. Hanna is pioneering techniques in induced pluripotency and reprogramming of adult cells. He was the lead researcher in a study that showed how further-modified IPS cells could be used to treat sickle-cell anemia in mice, the first proof of concept of the therapeutic application of IPS. He published 60 scientific articles in leading journals.